問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Digestive System Department

Division of General Internal Medicine

國立臺灣大學醫學院

Division of General Internal Medicine

更新時間：2023-09-19

梁嘉德LIANG, JA-DER
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 9 個月

Recruiting Trial

16Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

梁嘉德

List

34Cases

2018-03-31 - 2026-04-20

IIT

Phase I/II

Active
A Phase I/II Open Label Study to Evaluate Safety and the Prophylactic Effect on Recurrence of Anti-PD1 Monotherapy, P1101 Monotherapy, and Sequential Administration of P1101 and Anti-PD1 After Curative Surgery of HBV-related HCC

  • Condition/Disease

    Hepatocellular Carcinoma

  • Test Drug

    P1101

Participate Sites
1Sites

Recruiting1Sites

2024-07-15 - 2026-08-31

Phase I

Active
A Phase 1, Multicenter, Open-Label, Dose Escalation, and Dose Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of DCSZ11 as a Monotherapy and in Combination in Patients with Advanced or Metastatic Solid Tumors

  • Condition/Disease

    Advanced or Metastatic Solid Tumors

  • Test Drug

    injection

Participate Sites
5Sites

Recruiting5Sites

2019-07-01 - 2026-06-30

Phase III

Active
hase III, Randomized, Double-Blind, Placebo-Controlled, Multi Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation

  • Condition/Disease

    Hepatocellular Carcinoma

  • Test Drug

    Durvalumab (IMFINZI); Bevacizumab (Avastin)

Participate Sites
9Sites

Recruiting9Sites

2023-10-31 - 2027-08-31

Phase III

Active
A Phase III, Multicenter, Randomized, Open-label Trial to Evaluate the Safety and Efficacy of Systemic Therapy With Regorafenib and Pembrolizumab Versus Locoregional Therapy With Transarterial Chemoembolization or Transarterial Radioembolization, for the First-line Treatment of Intermediate-stage Hepatocellular Carcinoma With Beyond Up-to-7 Criteria

  • Condition/Disease

    Carcinoma, Hepatocellular

  • Test Drug

    Regorafenib Keytruda injection/Keytruda

Participate Sites
8Sites

Not yet recruiting7Sites

Recruiting1Sites

2023-08-01 - 2028-06-30

Others

Not yet recruiting
A Phase Ib/II, Open-Label, Multicenter, Randomized Platform Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma (MORPHEUS-NEO HCC)

  • Condition/Disease

    Carcinoma, Hepatocellular

  • Test Drug

    注射液劑 注射液劑 注射液劑 注射液劑

Participate Sites
5Sites

Recruiting5Sites

2021-01-31 - 2026-06-30

Phase I/II

Active
Phase I/II Randomized, Double-Blind, First-in-Human Study of T-ACE Oil by Trans-Catheter Arterial Embolization or ChemoEmbolization (TAE/TACE) in Patients with Hepatocellular Carcinoma

  • Condition/Disease

    Hepatocellular Carcinoma(HCC)

  • Test Drug

    T-ACE Oil

Participate Sites
4Sites

Not yet recruiting1Sites

Recruiting3Sites

2025-01-01 - 2026-12-31

Others

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2022-09-01 - 2026-08-31

Others

Active

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2014-11-01 - 2015-12-31

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2019-12-01 - 2026-10-31

Phase I/II

Active
Phase I/II Study of PTX-9908 Injection as an Inhibitor of Cancer Progression in Patients with Non-Resectable Hepatocellular Carcinoma Following Transarterial Chemoembolization Treatment

  • Condition/Disease

    Hepatocellular Carcinoma

  • Test Drug

    PTX-9908 Injection

Participate Sites
2Sites

Recruiting2Sites

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB